August 7, 2017 04:59 PM EDTUpdated August 8, 06:58 AM
R&D

Fi­bro­Gen shares rock­et up on pos­i­tive PhII da­ta in id­io­path­ic pul­monary fi­bro­sis

John Carroll

Editor & Founder

Shares of Fi­bro­gen $FGEN soared 62% af­ter the mar­ket close on Mon­day as the San Fran­cis­co-based biotech gave in­vestors a sign that its mid-stage study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times